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Abstract 
Nonalcoholic fatty liver disease (NAFLD) affects roughly 30% of the general population and 
its prevalence is increasing worldwide, in particular in Western countries where it is projected 
to become the main cause of hepatocellular carcinoma (HCC) within 2025. Although the 
majority of NAFLD progressing towards HCC are individuals with advanced fibrosis, 
NAFLD-HCC frequently develops even in patients without cirrhosis. Family history and 
genetic factors play an important role in the pathogenesis of progressive NAFLD and of HCC. 
Our hypothesis is that both common and rare variants may have a role in influencing HCC 
predisposition. 
Aim of this study was (1) to evaluate whether the rs641738 C>T common genetic variant in 
the MBOAT7/TMC4 locus, the last genetic variant recently associated with NAFLD 
development and progression towards early phases of damage, also predisposes to HCC in 
patients stratified by the presence of severe fibrosis, and (2) to assess whether telomere 
attrition and inherited rare hTERT mutations associates with NAFLD-HCC development, 
since mutations in Telomerase gene have been linked to familial liver diseases. 
In the first part of the study, we found that the rs641738 T allele is associated with NAFLD-
HCC independently of fibrosis severity and of several confounders (allelic OR 1.65, 95% 
confidence interval 1.08-2.55; n=765), particularly in patients without advanced fibrosis 
(p<0.001). The rs641738 risk T allele is associated with reduced MBOAT7 expression, 
evaluated by qRT-PCR on liver biopsy, specifically in patients without severe fibrosis, and 
was more strongly associated with HCC development in this specific subgroup (p=0.02). 
Moreover, the number of PNPLA3, TM6SF2, and MBOAT7 risk alleles is associated with 
NAFLD-HCC development independently of clinical factors (p<0.001), but it did not 
significantly improve their predictive accuracy. The independent association between the 
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MBOAT7 risk variant and increased HCC risk has also been confirmed in a combined cohort 
of chronic hepatitis C or alcoholic liver disease patients without cirrhosis (n=1121). 
In the second part of the study, we found that telomere length, evaluated by qRT-PCR, is 
progressively reduced in 40 NAFLD-HCC vs. 45 NAFLD-cirrhosis (p=0.048) and 64 healthy 
controls (p=0.0006), independently of age and sex. We detected an enrichment of rare 
germline coding mutations in hTERT in NAFLD-HCC patients vs. controls, even after 
considering 78 European primary liver cancers. No mutations were found in NAFLD-
cirrhosis and local controls, and only one in 503 Europeans from the 1000Genomes Project. 
Thus, overall mutations frequency was 0.025 in cases vs. <0.001 in controls (p=0.0005 at 
Burden test). hTERT mutations occurred predominantly in females (p=0.03) and were 
predominantly located in the N-terminal template-binding domain of the gene (p=0.037 for 
specific enrichment). The frameshift Glu113Argfs*79 and the missense Glu668Asp damaging 
mutations co-segregated with liver disease in families. Besides Glu668Asp, the Ala67Val 
variant resulted in reduced intracellular protein levels in HEK-293 cells. These data suggest 
that telomere attrition and certain hTERT mutations are involved in the pathogenesis of 
NAFLD-HCC. 
In conclusion, the identification of new common prognostic marker, such as the MBOAT7 
rs641738 variant, in NAFLD patients and the evaluation of hTERT rare mutations in NAFLD-
HCC may improve HCC screening strategies, by assisting in the identification of subjects at 
risk even in the absence of severe fibrosis and of family members at high risk of progressive 
liver disease, respectively. In future, functional studies are needed in order to understand the 
exact role and the interplay of the several common and rare genetic variants which contribute 
to the molecular mechanisms that underlie the pathogenesis of NAFLD-HCC. 
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1.Introduction 
1.1 Epidemiology of hepatocellular carcinoma associated with     
nonalcoholic fatty liver disease  
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third cause of 
cancer-related mortality worldwide [1].  Nowadays chronic viral hepatitis due to HBV or 
HCV infection represents the main cause of HCC development. Nevertheless, because of the 
diffusion of the vaccination against HBV and the availability of new antiviral treatment, and 
of the pandemic of obesity and insulin resistance on the other side, nonalcoholic fatty liver 
disease (NAFLD) is projected to become the leading cause of HCC in Western countries 
within 2025 [1-4].  NAFLD is defined as the hepatic accumulation of neutral lipids greater 
than 5% of liver weight and affects 16-38% of the general population worldwide [5]. It is a 
leading cause of cirrhosis, the main risk factor for HCC, which is due to progressive fibrosis 
and represents per se a pre-cancerous condition. Although the growing rates of HCC may be 
due to the increased number of individuals with advanced fibrosis, NAFLD-HCC frequently 
develops without overt cirrhosis suggesting that steatosis directly promotes hepatic 
carcinogenesis [6-9]. However, progression of liver disease to cirrhosis and HCC is more 
frequent in the subgroup of patients who develop non-alcoholic steatohepatitis (NASH), a 
condition characterized by active inflammation and fibrosis [10].  
Established risk factors for disease progression in NAFLD include older age and presence of 
features of the metabolic syndrome, such as obesity, severe insulin resistance, and 
hypertension. Consistently, NAFLD-HCC patients are most commonly older males, with type 
2 diabetes (T2D) and meeting criteria for at least one feature of the metabolic syndrome. 
HCCs arising in patients with features of the metabolic syndrome are larger, more 
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differentiated and mainly occurred in the absence of significant fibrosis compared than those 
arising in chronic viral hepatitis [11].  
In addition, it has been estimated up to 30% of HCCs in industrialized countries develop in 
patients with cryptogenic cirrhosis, a condition which is retained to stem in the majority of 
cases from burnt-out NASH [3, 12, 13]. 
Several epidemiological studies established an association between overweight and obesity, 
that are considered the major determinants of insulin resistance and NAFLD, and higher risk 
to develop HCC (17% and 89% respectively compared to normal weight). Furthermore the 
relationship linking obesity to HCC risk is stronger in male than in female [14, 15].  Even 
diabetes has been independently correlated to HCC onset in large epidemiological studies, 
where it was found that among men affected by T2D the risk for HCC was doubled [16, 17].  
On one hand, these data suggest that obesity and diabetes are the major epidemiological 
determinant of HCC incidence in Western countries. On the other hand, patients with 
progressive NAFLD are mostly unaware of being affected by a progressive form of liver 
disease. Therefore, due to the very high prevalence of NAFLD, occurrence in patients without 
advanced fibrosis, and lack of diseases awareness, classic screening strategies for the 
detection of early HCC are ineffective [1]. This renders the development of new noninvasive 
biomarkers able to stratify the risk of HCC development in NAFLD patients a public health 
priority. 
 
1.2 Pathogenesis of hepatocellular carcinoma (HCC) associated with 
nonalcoholic fatty liver disease (NAFLD) 
The mechanisms linking NAFLD to liver disease progression towards HCC have not yet been 
identified. Anyhow several pathways may be activated in obesity and diabetes favoring a 
tumor-promoting environment distinguishing the pathogenesis of NAFLD-HCC from that of 
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other etiologies [1, 3, 18, 19]. First of all, increased cancer risk is associated with a low-grade 
of chronic inflammation, a manifestation typical of obesity and metabolic syndrome. Indeed, 
adipose tissue expansion promotes the release of pro-inflammatory cytokines, namely tumor 
necrosis factor alpha (TNFα) and interleukin 6 (IL6) both potent activators of key oncogenic 
signaling pathways [20]. Furthermore, obesity alters the release of adipokines reducing the 
level of those with anti-inflammatory effects such as adiponectin and arising the level of those 
with pro-inflammatory and fibrogenic effects, such as leptin [21, 22].  
Even though this mechanism remain to be elucidated, cancer cells proliferation rate and HCC 
poor prognosis correlate with increased lipogenesis and accumulation of lipid droplets, 
suggesting that increased availability of fatty acids in hepatocytes may support HCC cells 
growth [23, 24]. 
Lipotoxicity may also contribute to HCC development by interfering with intracellular 
signaling pathways. Lipid peroxides and free radicals generated by increased rates of fatty 
acids oxidation, may induce mitochondrial dysfunction and endoplasmic reticulum stress thus 
altering gene transcription [25, 26]. 
Overall the factors listed above collectively induce hyperinsulinemia, resulting in increased 
bioavailability of insulin-like growth factor-1 (IGF1) which in turn promotes cellular 
proliferation and inhibits apoptosis [27]. 
Finally, some studies have been conducted in order to identified the biomarkers able to 
distinguish the pathogenesis of HCC according or not to the presence of cirrhosis. The 
deregulation of the Wnt/β-catenin signaling pathways seems to be specific of HCC onset in 
the absence of advanced liver fibrosis [11]. The activation of hepatic stellate cells (HSCs) is a 
major step in the development of cirrhotic HCC, however these cells not only secrete collagen 
that results in liver fibrosis, but may even produce several growth factors (senescence-
associated secretory phenotype – SASP) which stimulate oncogenic pathways contributing to 
the expansion of neoplastic clones [28]. Interestingly, signs of cellular senescence and SASP 
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have been observed in HSCs not related to fibrotic areas but located in proximity of NAFLD-
HCC lesions, indicating that these cells may contribute to the development of HCC also in the 
absence of cirrhosis [29]. 
 
1.3 Role of genetics in NAFLD progression towards HCC  
Genetic factors have been shown to influence disease progression in NAFLD, and family 
history remains the main risk factor for HCC development [10, 30]. The common genetic 
polymorphism rs738409 C>G encoding for the I148M variant in Patatin-like phospholipase 
domain-containing protein 3 (PNPLA3 or adiponutrin) has been established as the common 
genetic determinant of hepatic fat content and of progressive NAFLD [31-35]. The 
mechanism is related to accumulation of the mutated protein [36], which interferes with lipid 
droplets remodeling in hepatocytes [34, 37, 38], and with retinol release by hepatic stellate 
cells [39, 40]. The PNPLA3 variant predicts HCC development in European patients with 
NAFLD [41] and also in individuals affected by other liver diseases associated with steatosis, 
namely alcoholic liver disease (ALD) and chronic hepatitis C (CHC) [42]. This evidence 
suggests that this genetic risk factor may be helpful to select high-risk individuals for 
screening [42-44], but it has a low sensitivity to be used as single prognostic biomarker [45].  
The rs58542926 E167K variant in Transmembrane 6 superfamily member 2 (TM6SF2) also 
predisposes to progressive NAFLD by altering the secretion of very low-density lipoproteins 
[46-48], but its direct role in HCC predisposition is disputed [47, 49].  
More recently, it has been found that the rs641738 C>T sequence variant in the Membrane 
bound O-acyltranferase domain containing 7/ Transmembrane channel like 4 
(MBOAT7/TMC4) locus, involved in phospholipids remodeling, predisposes to cirrhosis 
development in individuals with excessive alcohol intake [50], and to the development and 
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the progression of NAFLD in individuals of European descent [51]. However, whether the 
rs641738 variant is also associated with HCC risk is still unknown. 
Besides the validated common genetic risk factors influencing lipid metabolism, the influence 
of variants involved in fibrogenesis has recently been described. Fibrosis stage and liver 
disease progression are strictly linked to cell senescence. Consistently, hepatocyte expression 
of p21, playing a pivotal role in the induction and maintenance of cellular senescence, was 
associated with fibrosis stage in NAFLD and increase liver related morbidity and mortality 
[52]. p21 is encoded by the Cyclin-dependent Kinase 1A (CDKN1A) gene. The rs762623 
G>A variant in the promoter region of CDKN1A, inducing a reduction in p21 expression 
level, has been associated with the development but not the progression of fibrosis in NAFLD 
independently from well recognized PNPLA3 I148M status [53]. Interestingly, CDKN1A 
variants have previously been described in association with rapid progression of idiopathic 
pulmonary fibrosis, a degenerative condition characterized by cellular senescence and 
impairment of telomeres [54, 55].  
Consistently, genetic data indicate that NAFLD is commonly observed in patients with 
telomeropathies, suggesting that steatosis may either be a consequence of hepatocellular 
senescence, as also observed in animal models, or a trigger for liver disease progression [56, 
57]. Indeed, loss of function germline mutations in the telomerase reverse transcriptase 
(hTERT) can predispose to a spectrum of familial liver diseases characterized by steatosis [56] 
and possible evolution to cirrhosis and HCC [58, 59]. In keeping, we previously reported the 
occurrence of NAFLD-HCC in a patient with a rare germline hTERT loss-of-function 
mutation [60]. Furthermore, it has also been reported that rare mutations inducing Mendelian 
diseases due to severe derangements in the function of encoded proteins may predispose to 
NAFLD-HCC. Indeed, mutations in Apolipoprotein B (APOB) may explain some familial 
cases through predisposition towards development of severe steatosis caused by 
hepatocellular retention of lipids [61]. 
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1.4 The MBOAT7 rs641738 common variant is a risk factor for NAFLD 
onset and progression 
The rs641738 C>T polymorphism located in the region of chromosome 19 proximal to the 
MBOAT7 gene, has been identified as a risk factor for cirrhosis development in a genome 
wide association study conducted in a cohort of alcohol abusers [50]. Afterwards, the impact 
of this variant on hepatic fat accumulation and metabolism has been demonstrated in two 
different independent cohorts: the Dallas heart study (DHS), a multiethnic population study 
conducted in Texas, and the Liver biopsy cross-sectional cohort, including European patients 
at risk of NASH. The T allele was associated with the entire spectrum of histological liver 
damage related to NAFLD: from steatosis, to necro-inflammation and early stages of fibrosis 
[51].  
The MBOAT7 protein is involved in Lands’ cycle regulating phospholipid acyl-chain 
remodeling. Particularly, it catalyzes the transfer of polyunsaturated fatty acids such as 
arachidonoyl-CoA to lyso-phosphatidylinositol and other lyso-phospholipids, thereby 
allowing to achieve an adequate level of desaturation [51]. The rs641738 T allele is associated 
with reduced MBOAT7 expression and consequently alters phosphatidyl-inositol plasma and 
hepatic composition [51, 62].  
 
1.5 hTERT mutations and telomere shortening are risk factors for liver 
disease progression 
Telomeres are simple repeat non coding DNA sequence (TTAGGG) located at the end of 
each chromosome. Their main function is chromosome capping in order to avoid 
chromosomes erosion by nuclease and chromosomes end-to-end fusion. During each round of 
cell division, telomere length reduces due to the inability of polymerase to fully replicate the 
terminal chromosomal segment, functioning as a “mitotic clock” to sense cell aging. When 
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telomeres become critically short, a DNA-damage program is activated leading to apoptosis 
or cell senescence (due to the Hayflick limit) [55, 63]. Telomere attrition is exacerbated in 
degenerative conditions characterized by chronic injury and regeneration with accelerated cell 
turnover [64]. Thus, limiting the replicative capacity of cells and the number of cells 
participating in tissue regeneration, shortened telomeres play a causal role in the pathogenesis 
of liver fibrosis [65-69]. Reduction of telomere length is considered a hallmark of cirrhotic 
tissue independently of the etiology of liver disease (e.g. viral hepatitis, autoimmune hepatitis, 
alcohol abuse…) [68]. A causal role of telomere shortening in fibrosis progression has been 
experimentally demonstrated: TERT deficient mice, after three generations, developed 
shortened telomeres and displayed diminished capacity for liver regeneration, and accelerated 
development of cirrhosis after liver injury. On the contrary, overexpression of TERT activity 
improved liver function and protected from development of hepatic steatosis and fibrosis [57]. 
Telomere length is a strongly hereditable tract. Consistently, genetic studies have proven that 
mutations in Telomerase represent the underlying cause of accelerated telomere shortening 
and organ failure. A significant enrichment of germline missense mutations in the hTERT and 
hTERC genes was observed in both a US cohort and a larger series of German patients with 
cirrhosis of different etiologies [59]. These mutations impaired hTERT enzymatic activity, as 
they were associated with reduced telomere length in the peripheral blood of patients and 
reduced telomerase activity in vitro [58]. These observations indicate that, in at least a 
proportion of patients who developed cirrhosis, fibrosis progression may be favored by 
genetic risk variants facilitating telomere shortening and cell senescence in the presence of 
triggering factors.  
In this context, telomere shortening may favor carcinogenesis by directly facilitating genomic 
instability. Indeed, shortened telomeres have been associated with the typical karyotipic 
alterations in HCC (chromosome 8 alterations), especially in the presence of TP53 mutations 
[70, 71]. Moreover, loss of hTERT has been shown to affect the overall configuration of 
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chromatin and to diminish the capacity for DNA repair of double strand breaks (DSB) [72]. 
Therefore, current data suggest a model whereby telomere shortening drives chromosomal 
instability during early stages of hepatic carcinogenesis, while telomerase re-activation is 
involved in progression to malignancy in another subset of tumors, as it confers cellular 
immortalization. Indeed, in HCC tissues, long telomeres and increased Telomerase activity 
were shown to be significant poor prognostic factors, associated with clinic-pathological 
features of aggressive behavior [73]. 
Thus, HCC tumor progression is associated with the reactivation of Telomerase, which is 
necessary for the immortalization of the neoplastic clone [74, 75].  hTERT promoter 
mutations, the most frequent somatic genetic alteration in HCC [76, 77], represent an 
important mechanism of reactivation of Telomerase during hepatocarcinogenesis by creating 
new binding site for specific transcription factors which consequently induce hTERT 
overexpression [78, 79], whereas in other cases overexpression may be related to HBV 
insertional mutagenesis or duplication. 
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2. Aim  
NAFLD has a high and increasing prevalence in western countries. Although the growing 
rates of NAFLD progressing towards HCC may be due to the increased number of individuals 
with advanced fibrosis, NAFLD-HCC frequently develops without overt cirrhosis suggesting 
steatosis directly promotes hepatic carcinogenesis [6, 7]. The complexity of the clinical 
manifestation renders patients mostly unaware of being at risk and classic HCC screening 
strategies aimed at early diagnosis and curative treatment unfeasible. Family history and 
genetic factors play an important roles in the pathogenesis of progressive NAFLD and of 
HCC [10, 30], however there is a lack of a common prognostic marker able to identify 
NAFLD patients at risk to progress towards cancer.  
Our hypothesis is that both common and rare variants may have a role in influencing rare 
diseases pathogenesis. Common genetic risk factors in combination with acquired risk factors, 
thanks to their high frequency in the general population and easy detection, maybe useful 
biomarkers to select subjects at risk of disease development. Rare genetic variants most likely 
deleterious, due to their very low frequency, may have a direct pathogenic role. 
Thus aim of the first part of this study was (1) to evaluate whether the MBOAT7 rs641738  
common genetic variant predisposes to HCC in patients with histologically confirmed 
NAFLD stratified by the presence of severe fibrosis. Moreover, progression of liver disease 
towards cirrhosis and possible HCC has been associated with inheritance of hTERT and 
hTERC mutations [56, 80] and older age and duration of liver disease remain among the 
major and more validated risk factors for liver disease progression [81, 82]. Thus, the aim of 
the second part of this study was (2) to assess whether telomere attrition and inherited rare 
hTERT mutations predispose to NAFLD-HCC development. We therefore compared 
peripheral telomere length and the frequency of hTERT rare germinal mutations between 
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European individuals with NAFLD-HCC and controls with NAFLD cirrhosis and without 
liver disease. 
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3.Material and methods 
3.1 Study design 
 
Study design is shown in figure 1. We investigated the role of common and rare genetic 
factors in the pathogenesis of NAFLD-HCC. (1) Briefly, in the first part of the project we 
analyzed the prevalence of the common genetic variant rs641738 in the MBOAT7 locus in a 
large NAFLD cohort according to the presence of HCC and advanced fibrosis. We 
subsequently evaluated the impact of the risk variant on hepatic MBOAT7 expression in 
patients stratified by fibrosis severity. Furthermore, we validated the association of the variant 
with HCC development in patients affected by other liver diseases of whom steatosis 
influences progression, namely alcoholic liver disease (ALD) and Chronic hepatitis C (CHC).  
(2) In the second part, we investigated the presence of rare germline hTERT coding mutations 
in NAFLD-HCC. We defined rare coding mutations as variations with allelic frequency 
<0.001, according to two of the largest frequency database available namely ExAC (Exome 
Aggregation Consortium) Non-Finnish European (NFE) population and ESP (Exome 
Sequencing Project) European-American (EA) population.  Furthermore, we evaluated 
telomere length on a discovery cohort of Italian NAFLD-HCC, NAFLD-cirrhosis and healthy 
individuals of comparable age and sex distribution. We attempted replication in a validation 
cohort including both Italian and Northern European subjects with NAFLD, who developed 
primary liver cancer (PLC). We subsequently conducted family studies to test for segregation 
of the hTERT mutations with liver disease. Finally, we examined the functional effects of the 
coding mutations identified by bioinformatics using a combination of in silico prediction tools 
and in vitro by cell studies with overexpression of recombinant wild-type and mutated 
proteins.
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Figure 1. Study design
18 
 
3.2 Patients  
 
In this study, we collected samples of patients enrolled in several Italian and a UK centers, 
which joined the “Epidemic study group investigators”, founded for the study of genetic 
factors influencing the progression of NAFLD towards HCC. The cases under study have 
been collected along several years from 2008 to 2015. For this reason the two different part of 
this study (investigating common and rare genetic variants respectively) are based on different 
numbers of NAFLD-HCC patients according to the period in which the projects have been 
developed. Moreover, differences in the number of patients involved may be related to the 
different quantity and quality of the samples collected not always suitable for each technique 
that we performed (for example sequencing required better quality and higher quantity of 
DNA compared to genotyping). No selection in NAFLD-HCC group collection has been 
made according to the clinical features of the patients enrolled.  
All patients included in this study were tested for secondary causes of steatosis including 
alcohol abuse (≥ 30/20 g/day in M/F) and the use of drugs known to precipitate steatosis. 
Viral and autoimmune hepatitis, hereditary hemochromatosis, Wilson’s disease, alpha-1-
antitrypsin deficiency and present or previous active infection with HBV and HCV were ruled 
out using standard clinical and laboratory evaluation, as well as liver biopsy features. 
Diagnosis of HCC was based on the EASL–EORTC Clinical Practice Guidelines for the 
management of hepatocellular carcinoma [83]. 
The study protocol was conformed to the ethical guidelines of the 1975 Declaration of 
Helsinki, was approved by the Ethical Committee of the Fondazione IRCCS Ca’ Granda of 
Milan, as well as by the other involved Institutions, and was performed according to the 
recommendations of the hospitals involved. Informed consent was obtained from each patient. 
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3.2.1  Patients investigated for the association of MBOAT7 rs641738 common genetic 
variant with NAFLD-HCC 
We enrolled 132 consecutive unrelated patients with NAFLD-HCC of Italian descent, referred 
between January 2008 and January 2015 to the Fondazione IRCCS Ca’ Granda Policlinico 
Hospital of Milan (n=35), S. Maria della Misericordia Hospital of Udine (n=16), Città della 
Salute e della Scienza University Hospital of Torino (n=46), Policlinico Gemelli Roma 
(n=34), University of Palermo (n=1), for whom DNA samples were available. In the absence 
of liver biopsy, diagnosis of NAFLD required detection of ultrasonographic steatosis plus at 
least one criterion of the metabolic syndrome.  
As controls we selected Italian-ancestry patients with histologically confirmed NAFLD 
followed at the same referral outpatient Hepatology services during the same study period 
(n=633; n=351 for Milan and n=282 from Palermo)[48, 84], from a recently published 
database [51], who did not develop HCC during follow-up.  
Advanced fibrosis was defined in the presence of fibrosis stage F3-F4 [85], when liver biopsy 
was available. In HCC patients with radiological diagnosis, advanced fibrosis was defined in 
the presence of clinical, endoscopic or ultrasonographic signs of portal hypertension or 
cirrhosis (n=46), or of liver stiffness ≥ 8.4 kPa evaluated by elastometry (n=3), or by a 
positive NAFLD fibrosis score (n=5) [86]. Obesity was defined when BMI>30 Kg/m
2
. All 
NAFLD patients without HCC included in the study underwent liver biopsy, while among 
those who developed HCC, fibrosis staging was histologically performed in 78 (59%) of the 
cases. Clinical features of subjects included according to the presence of HCC are shown in 
Table 1.  
 
 
 
 
20 
 
Table 1. Clinical features of 765 NAFLD patients stratified by HCC diagnosis. 
 Hepatocellular carcinoma p 
 Yes (n=132) No (n=633)  
Age, years 67.0±8.8 47.5±12.3 <0.001 
Sex, Female 25 (19) 163 (26) 0.25 
Obesity, yes 39 (32) 202 (32) 0.99 
T2DM, yes 84 (64) 124 (20) <0.001 
Severe fibrosis, F3-4 111 (84) 99 (16) <0.001 
PNPLA3, I148M   <0.001 
I/I 31 (23) 231 (36)  
I/M 55 (42) 283 (45)  
M/M 46 (35) 120 (19)  
TM6SF2, E167K   0.30 
E/E 109 (83) 539 (85)  
E/K 19 (14) 88 (14)  
K/K 4 (3) 7 (1)  
MBOAT7, rs641738 C>T   0.003 
C/C 26 (20) 213 (34)  
C/T 69 (52) 285 (45)  
      T/T 37 (28) 135 (21)  
 
( ): % values; T2DM: type 2 diabetes mellitus. Comparisons were performed by logistic 
regression setting HCC as dependent variable, and the association of genetic variants was 
analyzed assuming additive models. 
 
We next evaluated the impact of the rs641738 variant on HCC risk in an Italian multicenter 
cohort of patients with chronic hepatitis C (CHC; n=994) and alcoholic liver disease (ALD; 
n=757), stratified by the presence of cirrhosis. Of CHC patients, 815 were from the well-
described histological Milan cohort [87, 88], whereas the remaining 179 were HCC cases 
developed in CHC patients, which were previously described by our group (Milan HCC 
cohort, where presence of cirrhosis was carefully assessed) [89]. 
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ALD patients with and without HCC included 171 patients from the Milan center, which were 
partly described previously (again the Milan HCC cohort), and for whom liver disease was 
evaluated by histology or as described above for NAFLD [89]. We also considered 586 
consecutive individuals, who were admitted to the Outpatient Clinic at the Department of 
Clinical Medicine, Policlinico Umberto I, Rome (Italy) for alcohol abuse or dependence 
between 2005 and 2014, for whom DNA samples were still available and genotyping was 
successful. This series comprised 384 previously described individuals [90], and 202 
additional patients subsequently enrolled using the same criteria [90]. At-risk alcohol 
consumption was defined as ≥3/2 alcohol units per day for M/F, respectively. Diagnosis of 
cirrhosis was based on the presence of at least one of the following features: (I) current or past 
cirrhosis complications; (II) the presence of at least two parameters among 
hyperbilirubinaemia, hypoalbuminaemia, prolonged prothrombin time, low platelet count, 
irregular liver surface at ultrasound/CT, reduced portal vein flow at ultrasound, 
gastroesophageal varices at endoscopy, or by histological analysis. Individuals with other 
coexistent liver diseases were excluded. Clinical features of this cohort are presented in Table 
2.  
Table 2. Clinical and genetic features of 994 patients with chronic hepatitis C (CHC) 
and 757 with alcoholic liver disease (ALD). 
 CHC ALD 
n= 994 757 
Age, years 60±13 50±12 
Sex, Female 390 (39) 176 (23) 
Cirrhosis, yes 397 (40) 233 (31) 
HCC, yes 250 (25) 113 (15) 
PNPLA3, I148M 505/386/103 
(51/39/10) 
309/330/117 
(41/44/15) 
TM6SF2, E167K 910/84 
(92/8) 
639/113/5 
(84/15/1) 
MBOAT7/TMC4, rs641738 C>T 307/452/235 
(31/45/24) 
217/378/161 
(29/50/21) 
( ): % values; HCC: hepatocellular carcinoma. 
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3.2.2  Patients investigated to study the role of telomere and hTERT rare coding mutations 
in NAFLD progression towards HCC 
In phase 1, we enrolled 40 patients with NAFLD-HCC: 20 from Policlinico Hospital of 
Milan, 4 from S. Giovanni Battista Hospital of Turin, one from the Gastroenterology unit of 
Palermo and the remaining 15 from the S. Maria della Misericordia Hospital of Udine. 
Additionally, 45 patients affected by NAFLD cirrhosis were enrolled in order to confirm the 
association of the mutations eventually found with the carcinogenic phenotype (20 from 
Palermo and 25 from Milan). For all the patients complete clinical data and follow up are 
available in Table 3. Missing data (representing less than 5% for each category) have been 
replaced by the median for each category. These samples, belonging to the Discovery cohort, 
were collected from January 2012 until December 2013. 
Finally, we analyzed a local ethnically matched control group of comparable sex distribution 
including sixty-four healthy blood donors without clinical and biochemical evidence of liver 
disease and no alcohol abuse [91].  
In the second phase of the study we examined a validation cohort collected after January 
2014, including 78 patients affected by NAFLD-PLC, two of whom had intrahepatic 
cholangiocarcinoma (28 from the Freeman Hospital of Newcastle upon Tyne, 24 from Turin, 
25 from the Policlinico Gemelli of Rome and one from Milan). We did not exclude NAFLD-
associated intrahepatic cholangiocarcinoma in the validation cohort, since we could not rule 
out that germline mutations in hepatic stem cells might give rise to cancers with different 
phenotypes. Clinical features are shown in Table 3.  
Telomere length in intra-tumoral liver specimens was also evaluated in 5 Italian HCC 
patients, whose clinical features are listed in Table 4. 
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Table 3. Clinical features of subjects included in the study. 
                 Discovery cohort Validation cohort 
 Healthy  
(n=64) 
Cirrhosis  
(n=45) 
HCC 
(n=40) 
p PLC 
(n=78) 
p 
Age, years 59.1±6.6 58.8±8.7 66.3±9.5 <0.0001 67.5±8.4 <0.0001 
Sex, F 19 (30) 15 (33) 13 (33) 0.606 11 (14) 0.0239 
BMI 25.5±2.6 30.5±4.3 28.6±4.0 0.0011 30.3±5.4 <0.0001 
T2DM, y 0 29 (64) 24 (60)
 
<0.0001 45 (58) <0.0001 
Fibrosis, F3-4 0  45 (100) 32 (80) <0.0001 61 (78) <0.0001 
Italian 
ancestry, y 
64 (100) 45 (100) 40 (100)  50 (64)  
PNPLA3, 
I148M 
   0.0086  <0.0001 
I/I 36 (56) 9 (20) 15 (37)  16 (21)  
I/M 24 (38) 23 (51) 14 (35)  36 (46)  
  M/M 4 (6) 13 (29) 11 (28)  26 (33)  
 
PLC: primary liver cancer; ( ): % values; y: yes; T2DM: type 2 diabetes mellitus; p: p value 
calculated as HCC versus Healthy subjects. 
 
Table 4. Clinical features for characterization of HCC patients for whom biopsy samples 
have been analyzed. 
  
 
 
 
 
 
 
 
( ): % values; y: yes; T2DM: type 2 diabetes mellitus. 
 
 
HCC 
(n=5) 
Age, years 69.8±4.4 
Sex, F 1 (20) 
BMI 33.7±8.3 
T2DM, y 5 (100) 
Fibrosis, F3-4 5 (100) 
Italian Ancestry 5 (100) 
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3.3 Genotyping 
Patients were genotyped for rs738409 (PNPLA3 I148M) and rs58542926 (TM6SF2 E167K), 
as previously described [48]. The rs641738 (located within TMC4 coding sequence, 
chr19:54676763 positive strand, p.G17E protein variant) and rs8736 (located within the 3’-
untranslated region – UTR – of MBOAT7) MBOAT7/TMC4 locus genotyping has been 
performed in duplicate by TaqMan 5’-nuclease assays (Life Technologies, Carlsbad, CA). 
Genotyping success rate was >98%. The duplicate genotype concordance rate was 100%.  
 
3.4 hTERT sequencing 
The presence of coding mutations in hTERT sequence was evaluated by Sanger Sequencing 
on DNA previously extracted from peripheral blood leukocytes by phenol-chloroform 
extraction. The primers used for amplification and sequencing of the whole hTERT sequence, 
including the 16 exons and intron-exon boundaries, are listed in Table 5. 
In order to evaluate the presence of known acquired somatic activating mutations, hTERT 
promoter sequencing was performed as previously described on DNA extracted from liver 
specimens of 5 NAFLD-HCC patients [77, 92]. 
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Table 5. Primers used for PCR and Sanger sequencing in hTERT sequencing analysis.  
Exon Sequence 5’      3’ 
1-2 Forward GAGTTTCAGGCAGCGCTGCGT 
1-2 Reverse CTTGTCGCCTGAGGAGTAGAG 
1-2 Seq Forward* CAACACGGTGACCGACGCACT 
1-2 Seq Reverse* CAGGTGAACCAGCACGTCGTC 
2 Forward CAGGACGCGTGGACCGAGTGA 
2 Reverse GTGAACCTCGTAAGTTTATGC 
3 Forward GTGATCTGGATGTGGCATGT 
3 Reverse GGTGTTCCAGGACTTCGAGA 
4 Forward GTCTGTTGTCTGGCTGAGCA 
4 Reverse GCTCAAACGCACTTCTGTTTA 
5 Forward ACTTGGCCGGATCCACTT 
5 Reverse CACTCCCAAGGTCCAGCA 
6 Forward CGTGGCCACTGTCAGTCT 
6 Reverse CAGAGACACACATCCTGGACA 
7 Forward CCACATTTGTGGCTCATGC 
7 Reverse TCATGAGCCCAGTGATTGC 
8 Forward GTCCTGCCTGTCTCAGCAC 
8 Reverse GAAGGGGCAGGAGAGAGGT 
9 Forward AGTGTACGCATGTCCAGCAC 
9 Reverse AATCAACCCCCACCCAAG 
10 Forward CCGCTTTGGAGAATGTTACTT 
10 Reverse TGGAGGTCCCCACAGACA 
11 Forward TCAGGTTACCTCCTGGGTGA 
11 Reverse CCACACGGAAGCAGAGGT 
12 Forward GCAGGAGGCTCTTTGGAG 
12 Reverse TCCTGAACTCTGAACTCTGTG 
13 Forward CCAGAGAGGTTTCTACCGTTT 
13 Reverse GGTCAGAGGTGAGCAGAGC 
14 Forward ACGAGCACCGTCTGATTAGG 
14 Reverse AGGCACTGCTGCCACTGA 
15 Forward CAGCTTTCCGGTGTCTCCT 
15 Reverse GGGCGTTCAAGGATGACC 
16 Forward CACCTCTGGCCTCTTCTGG 
16 Reverse GACAGGGCTGCTGGTGTCT 
 
*Primer used only for sequencing 
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3.5  Gene expression analysis 
Expression of MBOAT7 and TMC4 was determined in two different subsets of patients. The 
first one was made of 98 severely obese patients, with a very low prevalence of advanced 
liver fibrosis, and has previously been described in details [51]. This was used to analyze the 
association of a 3’-untranslated region MBOAT7 locus variant, rs8736 possibly influencing 
MBOAT7 mRNA stability, with MBOAT7 expression.  The second one was made up of 47 
patients from the Hepatology service, and was characterized by a higher prevalence of liver 
fibrosis. Clinical features of these patients are presented in Table 6. This was used to evaluate 
the impact of liver fibrosis on the association between the rs641738 variant and MBOAT7 
expression. 
MBOAT7 expression was quantified as previously described [51]. Association analysis 
between rs641738 variant (additive model) and gene expression, and linkage with rs8736 
were conducted by the PLINK v1.07 genetic analysis software. 
 
Table 6. Clinical and genetic features of 47 patients from the Milan Hepatology service, 
for whom hepatic gene expression analysis was available. 
 
 Mean±SD; n (%) 
Age, years 48±10 
Sex, F 13 (28) 
BMI, Kg/m
2
 30.3±5.1 
T2DM or IFG 18 (38) 
NASH, yes 39 (83) 
Fibrosis, stage F2-F4 26 (55) 
PNPLA3, I148M 11/23/13 (23/50/28) 
TM6SF2, E167K 35/12 (74/26) 
MBOAT7/TMC4, rs641738 C>T 22/19/6 (47/40/13) 
 
T2DM: type 2 diabetes mellitus. 
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3.6 Telomere length measurement 
DNA was obtained from peripheral blood leukocytes or liver biopsies by phenol-chloroform 
extraction. Quality control was performed by evaluating 260/280 nM absorbance ratio and by 
polyacrylamide gel electrophoresis. Mean telomere length was measured by quantitative real-
time polymerase chain reaction (qPCR), as previously described [93-96]. Briefly, PCR was 
conducted in triplicate in a 7500Fast Real Time PCR System (Life Technologies, Foster City, 
CA) and results are presented as ratio of telomere repeat copy number to 36B4 single gene 
copy number, calculated considering the relative quantity of the two distinct PCR products. 
 
3.7 Mutagenesis, cloning and overexpression of hTERT variants 
Wild type hTERT cDNA was synthesized and cloned in the pcDNA 3.1 vector with a V5 
epitope tag at the C-terminus by GeneArt Gene Synthesis (Thermo Fisher Scientific, 
Rockford, IL, USA). Single base-pair changes resulting in an alanine to valine substitution 
(Ala67Val) or a glutamate to aspartate substitution (Glu668Asp) were introduced by overlap 
extension PCR cloning. Single base-pair changes resulting into a proline to leucine 
substitution (Pro193Leu) or a histidine to proline substitution (His296Pro) were introduced by 
site-directed mutagenesis. The PCR products were cloned in pcDNA 3.1 vector (pcDNA 3.1 
Directional TOPO Expression Kit; Invitrogen, Carlsbad, CA). The presence of the hTERT 
mutations and fidelity of each construct were confirmed by DNA sequencing. Human 
embryonic kidney cells (HEK-293) and immortalized human hepatic stellate cells (LX-2, 
kindly provided by Professor Scott L. Friedman, [97]) were cultured in DMEM (Dulbecco’s 
Modified Eagle Medium) containing 10% FBS (Fetal Bovine Serum). Expression plasmids 
(30 μg/T-75 flask) containing the human wild type hTERT or mutants, were used to transfect 
HEK-293 or LX-2 cells using Lipofectamine 3000 (Thermo Fisher Scientific) reagent 
according to the manufacturer’s protocol. After 48 h cells were collected. Cells were lysed in 
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M-PER® (Mammalian Protein Extraction Reagent, Thermo Fisher Scientific) containing 
complete protease inhibitors cocktail (Sigma-Aldrich, Saint Louis, Missouri, USA) and 
analyzed by Western blotting. The intensity of the Western blotting bands was measured by 
Image Lab Software (Bio-Rad) and expressed as arbitrary unit (AU). The highest value 
obtained was assigned as 1. 
 
3.8 Bioinformatics and statistical analysis  
For descriptive statistics, continuous variables are shown as mean and standard deviation, 
while categorical variables are presented as number and proportion. 
The odds of HCC for MBOAT7 rs641738 T alleles were estimated by logistic regression 
models, assuming an additive effect of rs641738, and adjusted for ethnicity, age, gender, 
BMI, IFG/T2DM, PNPLA3 I148M and TM6SF2 E167K genotypes (clinical and genetic 
factors previously associated with or candidate for liver disease evolution to HCC) [43, 47]. 
All genetic analyses in the first part of the study were performed assuming an additive model. 
Interactions among genes and between genes and environmental factors were tested by adding 
the corresponding gene*gene and gene*environment interaction terms to the multivariable-
adjusted regression model.  Population attributable risk (PAR) of genetic variants on HCC has 
been estimated as previously described [98]. A NAFLD-HCC risk score was developed as 
previously described [86]. 
Telomere lengths comparisons have been conducted by generalized linear model corrected for 
sex and age. 
All the variants found in the hTERT sequencing experiment were functionally annotated using 
the hTERT RefSeq reference transcript NM_001193376. We defined rare coding mutations as 
variations not present in dbSNP (release 147) and 1000Genomes Project (Phase 3) or 
described with a minor allele frequency (MAF) <0.001 according to ExAC-NFE and ESP-EA 
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populations. The rare variants identified were submitted to the ClinVar database 
(www.ncbi.nlm.nih.gov/clinvar/; submission ID: SUB2041085 (MDI-7607)). 
Burden test was performed using the collapsing method CAST (Cohort Allelic Sum Test) 
available in the R package AssotesteR (http://CRAN.R-project.org/package=AssotesteR). 
Briefly, the genotype of the rare coding mutations for the individual of each group of patients 
and controls was summarized and collapsed into a single genetic score, taking into account 
both the number of mutated alleles in each group and the mutation frequency in controls. The 
association of this score with the trait was tested using Fisher test. The association was 
considered statistically significant with p-values lower than 0.05.  
The impact of rare coding mutations on protein activity was predicted in silico by different 
bioinformatics algorithms including Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/), 
SIFT (http://sift.jcvi.org) and PROVEAN (http://provean.jcvi.org). 
Statistical analyses were carried out using the JMP 12.0 Statistical analysis software (SAS 
Institute, Cary, NC) and PLINK v1.07 [99]. P-values < 0.05 were considered statistically 
significant. The study methods and results have been reported according to the 
STROBE/STREGA guidelines for genetic association studies.  
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4.Results 
 
4.1 The MBOAT7 rs641738 variant increases the risk of hepatocellular 
carcinoma in European individuals without cirrhosis 
4.1.1 The NAFLD cohort  
The clinical features of NAFLD patients stratified by HCC diagnosis are presented in Table 1 
(Material and methods section). Patients who developed HCC were older (p<0.001), and had 
higher prevalence of type 2 diabetes (T2DM; (p<0.001)), and had more frequently advanced 
fibrosis (stage F3-F4; p<0.001) than those without who did not. In contrast, we did not detect 
significant differences in sex distribution and prevalence of obesity (p=NS).  
Concerning genetic risk factors, at univariate analysis development of HCC was associated 
with the I148M PNPLA3 variant (p<0.001). 
The clinical features of NAFLD-HCC patients according to the presence of advanced fibrosis 
are reported in Table 7. Patients who developed HCC in the absence of advance fibrosis 
(n=21, 17%) were more frequently males (p=0.040), and carriers of the MBOAT7/TMC4 
rs641738 risk T allele (p=0.006).  
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Table 7. Clinical and genetic features of 132 Italian patients with NAFLD-HCC 
stratified by the presence of severe hepatic fibrosis at diagnosis. 
 Severe fibrosis p 
 Yes (n=111, 83%) No (n=21, 17%)  
Age, years 66.3±8.3 68.3±12.3 0.49 
Sex, F 24 (22) 1 (5) 0.040 
Obesity, n 31 (28) 8 (38) 0.43 
T2DM, y 70 (63) 14 (67) 0.97 
PNPLA3, I148M   0.052 
I/I 22 (20) 9 (43)  
I/M 49 (44) 6 (29)  
M/M 40 (36) 6 (27)  
TM6SF2, E167K   0.27 
E/E 94(84) 15 (71)  
E/K 14 (14) 5 (24)  
K/K 3 (3) 1 (5)  
MBOAT7, rs641738 
C>T 
  0.006 
C/C 25 (23) 1 (5)  
C/T 60 (53) 9 (43)  
T/T 26 (24) 11 (52)  
 
 ( ): % values; T2DM: type 2 diabetes mellitus. 
 
4.1.2 The MBOAT7 locus rs641738 sequence variant is associated with HCC 
The frequency distribution of the MBOAT7 rs641738 C>T polymorphism in NAFLD patients 
stratified by the presence of HCC is shown in Figure 2A. There was a significant over-
representation of the rs641738 T allele in HCC vs. non-HCC NAFLD patients (p=0.003, 
Figure 2A and Table 1). In the NAFLD population, which was selected due to referral for 
suspected steatohepatitis and/or HCC, there was a borderline deviation from Hardy-Weinberg 
equilibrium for the frequency distribution of the rs641738 MBOAT7 variant (p=0.03 in both 
groups). However, the frequency distribution of the rs641738 variant did not violate Hardy-
Weinberg equilibrium in 243 unselected healthy control subjects (p=NS; Table 8). 
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Table 8. Frequency distribution of the rs641738 C>T variant in 243 healthy individuals 
with available DNA samples, normal liver enzymes with low probability of steatosis*. 
HWE p=0.36.  
rs61738 genotype N= % 
C/C 78 32 
C/T 113 45 
T/T 52 23 
 
* The full cohort was already described [100].  
The clinical features of NAFLD patients stratified by the rs641738 genotype are shown in 
Table 9. The rs641738 T allele was borderline associated with T2DM (p=0.05) in the overall 
cohort, but this was not confirmed in patients stratified by HCC diagnosis, and was possibly 
explained by the confounding effect of the association between both rs641738 T allele and 
T2DM with HCC. In HCC patients, the T allele was associated with obesity (p=0.035), and 
lack of advanced fibrosis F3-F4 (p=0.006). As expected, the rs641738 T allele was nearly 
associated with advanced fibrosis (stage F3-F4; OR 1.24, 95% c.i. 1.00-1.54; p=0.052). After 
stratification of patients for fibrosis severity (stage F0-F2 vs. F3-F4), the rs641738 T allele 
was associated with HCC in patients without (p<0.001; Figure 2B), but not in those with 
(p=0.55; Figure 2C) advanced fibrosis. 
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Table 9. Clinical features in 765 Italian patients with NAFLD stratified by MBOAT7 rs641738 polymorphism according to HCC diagnosis. 
               Hepatocellular carcinoma Overall 
 Yes No   
 rs641738 p rs641738 p rs641738 p 
 C/C C/T T/T  C/C C/T T/T  C/C C/T T/T  
n= 26 69 37  213 285 135  239 354 172  
Age, years 68±10 66±9 68±8 0.36 47±12 48±12 48±14 0.84 49±14 51±13 52±15 0.10 
Sex, Female 5  (19) 14 (20) 6 (16) 0.72 52 (24) 68 (24) 43 (32) 0.17 57 (24) 82 (23) 49 (28) 0.33 
Obesity, yes 4  (15) 24 (35) 12 (33) 0.035 66 (31) 94 (33) 42 (31) 0.92 70 (29) 117 (33) 54 (31) 0.36 
T2DM, yes 15 (58) 43 (62) 26 (70) 0.29 40 (19) 58 (20) 26 (19) 0.92 55 (23) 101 (28) 52 (30) 0.050 
Severe fibrosis, 
F3-F4 
25 (96) 59 (85) 27 (73) 0.006 30 (14) 41 (14) 27 (20) 0.17 55 (23) 100 (28) 54 (31) 0.052 
( ): % values; T2DM: type 2 diabetes mellitus. Comparisons were performed by logistic regression setting HCC as dependent variable, and the 
association with the MBOAT7 variant was analyzed assuming an additive model. 
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Figure 2. Frequency distribution of the MBOAT7 locus rs641738 T allele in 765 Italian 
NAFLD patients stratified by the presence of hepatocellular carcinoma (HCC). A) 
Overall cohort; B) patients with stage F0-F2 fibrosis; C) patients with stage F3-F4 fibrosis. 
Comparisons were performed by logistic regression setting HCC as dependent variable, and 
the association with the MBOAT7 variant was analyzed assuming an additive model.
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4.1.3 Independent predictors of NAFLD-HCC 
The independent predictors of NAFLD-HCC are presented in Table 10. At univariate analysis 
(left panel), development of HCC was associated with older age, T2DM, and presence of 
severe fibrosis (p<0.001 for all), whereas among the genetic factors with PNPLA3 I148M 
alleles (p<0.001) and MBOAT7 T rs641738 T alleles (OR 2.18, 95% c.i. 1.30-3.63; p=0.003).  
At multivariate logistic regression analysis including as independent variables noninvasive 
predictors of HCC (Model 1) such as age, sex, presence of obesity, T2DM, number of 
PNPLA3 I148M, TM6SF2 E167K, and MBOAT7 rs641738 T alleles (middle panel), HCC was 
associated with older age (p<0.001), male sex (p=0.045), T2DM (p<0.001), PNPLA3 I148M 
alleles (p=0.010), TM6SF2 E167K alleles (p=0.027), and MBOAT7 rs641738 alleles (OR 
1.81, 95% c.i. 1.24-2.69; p=0.002).  After further adjustment for the presence of severe 
fibrosis stage F3-F4 (Model 2), the TM6SF2 E167K (p=0.008) and MBOAT7 rs641738 T (OR 
per allele 1.65, 95% c.i. 1.08-2.55; p=0.021; OR for T/T vs. C/C 2.73, 95% c.i. 1.17-6.51; 
p=0.008) alleles remained significantly associated with HCC risk, whereas the effect of the 
PNPLA3 I148M variant was lost. A pooled estimate of the impact of the I148M variant on 
NAFLD-HCC risk in this cohort and a UK cohort [43] is presented in Table 11. This meta-
analysis confirmed that the I148M variant predisposes to HCC independently of the severity 
of fibrosis (OR 1.60, 95% c.i. 1.14-2.25; p=0.007). In model 1, the effect of MBOAT7 variant 
was larger in patients without severe fibrosis (OR per allele 2.78, 95% c.i. 1.04-8.71; 
p=0.050), whereas it was not significant considering only patients with severe fibrosis (OR 
per allele 1.19, 95% c.i. 0.78-2.03; p=0.3). 
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Table 10. Independent predictors of HCC in 765 Italian patients with NAFLD 
 
 Unadjusted Model 1 Model 2 
 OR  95%c .i. p OR 95%c .i. p OR 95%c .i. p 
Age, years 1.20 1.16-1.24 <0.001 1.19 1.15-1.23 <0.001 1.16 1.11-1.21 <0.001 
Sex, Female 0.57 0.41-1.06 0.09 0.52 0.27-0.99 0.045 0.45 0.21-0.91 0.026 
Obesity, yes 1.11 0.75-1.69 0.61 1.69 1.05-2.56 0.069 2.50 1.32-4.76 0.008 
T2DM, yes 7.18 4.81-10.84  <0.001 4.73 2.75-8.30 <0.001 3.33 1.75-6.44 <0.001 
Severe fibrosis, F3-F4 28.9 17.6-49.5 <0.001 NA NA NA 12.5 6.36-6.1 <0.001 
PNPLA3, n I148M alleles 1.70 1.32-2.21 <0.001 1.61 1.12-2.32 0.010 1.31 0.86-2.03 0.24 
TM6SF2, n E167K alleles 1.27 0.82-1.92 0.27 1.99 1.08-3.65 0.027 2.80 1.33-6.10 0.008 
MBOAT7, n T alleles 2.18 1.30-3.63 0.003 1.81 1.24-2.69 0.002 1.65 1.08-2.55 0.021 
 
OR: odds ratio of HCC, 95% c.i.: 95% confidence interval; T2DM: type 2 diabetes mellitus; n: number of at risk alleles. Comparisons were performed 
by logistic regression setting HCC as dependent variable, and the association of genetic variants was analyzed assuming additive models. Model 1: 
adjusted for age, sex, obesity, and T2DM; Model 2: further adjusted for the presence of advanced fibrosis; NA: not addressed. 
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Table 11. Pooled estimates of HCC risk in NAFLD patients for the presence of the 
PNPLA3 I148M variant. 
 
Genetic variant HCC No-HCC OR 95% c.i. p value 
Italian cohort 132 633 1.31 0.86-2.03 0.24 
UK cohort 100 275 2.26 1.23-4.14 0.008 
Pooled estimate 232 908 1.60 1.14-2.25 0.007 
 
Odds ratios (OR) and 95% confidence intervals (c.i.) were calculated for carriage of each 
genetic variant in the fully adjusted model (including for both studies age, sex, obesity/BMI, 
presence of type 2 diabetes, and severe fibrosis/cirrhosis). Pooled estimates (OR, 95% c.i.) 
were calculated by the inverse variance method (fixed effect model) by the Review Manager 
v.5 software (Cochrane collaboration). p=0.13 for heterogeneity between studies.  
 
4.1.4 Combined effect of acquired and common genetic risk factors for HCC 
The PAR of genetic risk factors of NAFLD-HCC, estimated based on Model 1 presented in 
Table 10, is presented in Table 12. These data suggest that the MBOAT7 T allele has a sizable 
impact on HCC risk in this specific cohort (estimate PAR 27%, 95% c.i. 2-49%), which was 
comparable to that of the I148M PNPLA3 variant. 
 
Table 12. Population attributable risk of HCC in 765 Italian patients with NAFLD for 
PNPLA3, TM6SF2, and MBOAT7 variants. 
 PAR 95% c.i. 
PNPLA3, I148M alleles 22% 5-38% 
TM6SF2, E167K alleles 8% 1-18% 
MBOAT7, rs641738 T alleles 27% 2-49% 
 
PAR: population attributable risk; 95% c.i.: 95% confidence interval. 
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In both multivariate models (Model 1 and 2), there was no significant interaction among 
genetic risk factors in determining HCC risk (p>0.1 for all). However, there was a significant 
interaction between the number of rs641738 T alleles carried and the presence of obesity in 
determining HCC risk (p=0.035 in Model 2, shown in Table 13). 
 
Table 13. Full model reporting the independent predictors of HCC in 765 Italian 
patients with NAFLD. 
 
 Full model (Model 3) 
 OR 95%c .i. p 
Age, years 1.17 1.13-1.22 <0.001 
Sex, Female 0.40 0.18-0.84 0.008 
Obesity, yes 2.99 1.56-5.90 0.008 
T2DM, yes 3.79 2.07-7.10  <0.001 
Advanced fibrosis, stage F3-F4 16.50 8.63-33.3 <0.001 
PNPLA3, number of I148M alleles 1.19 0.62-3.19 0.41 
TM6SF2, number of E167K alleles 3.07 1.48-6.59 0.002 
MBOAT7, number of T alleles 1.74 1.13-2.71 0.011 
MBOAT7, T alleles * Obesity, yes - - 0.035 
 
OR: Odd Ratio; 95% c.i.: 95% confidence interval. 
 
The relationship between the number of risk alleles among PNPLA3 I148M, TM6SF2 E167K, 
and MBOAT7 rs641738 T and HCC risk is presented in Figure 3. There was a significant 
association between the cumulative number of risk alleles and HCC (OR per allele 1.56, 95% 
c.i. 1.31-1.86; OR 9.25, 95% c.i. 3.83-22.8 between the extremes of the distribution; 
p<0.001). HCC risk was 9% in the 36% of the population with 0-1 risk alleles, 19% in the 
55% of the population with 2-3 risk alleles, and 31% in the 9% of the population with 4-5 risk 
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alleles. The association held constant after correction for other risk factors as in Model 2 (OR 
per allele 1.68, 95% c.i. 1.30-2.20; OR 13.4, 95% c.i. 3.71-51.5 between the extremes of the 
distribution; p<0.001).  
 
 
 
Figure 3. Risk of hepatocellular carcinoma according to the number of PNPLA3 I148M, 
TM6SF2 E167K, and MBOAT7 rs641738 C>T risk variants in 765 Italian patients with 
NAFLD. HCC: hepatocellular carcinoma; SE: standard error. Comparisons were performed 
by a multivariate logistic regression setting HCC as dependent variable, and the association 
with genetic risk factors (numbers of at risk alleles carried) was analyzed assuming an 
additive model. p<0.001 for the association of the number of risk alleles with HCC, both at 
unadjusted analysis and after adjustment for age, sex, obesity, T2DM, and presence of 
advanced fibrosis stage F2-F4. 
 
A combined risk score considering acquired and common genetic risk factors was developed 
to predict HCC: 1 / (1 + e ^ - ((-12.588 + (0.162 * age) + (0.404 * Sex: 1 if male, -1 if female) 
+ (0.259 * Obesity: 1 present, -1 absent) + (0.587 * T2DM: 1 present, -1 absent) + (1.299 * 
Severe Fibrosis: 1 yes, -1 no) + (0.442 * number of risk alleles))). The model had a 0.96 area 
under the receiving operating characteristic curve (AUROC). The optimal cutoff had 96% 
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sensitivity and 89% specificity for HCC in the present cohort (Figure 4). The corresponding 
AUROC of a model taking into consideration only clinical factors was slightly lower (0.94). 
In the subgroup of patients without severe fibrosis, the AUROC for clinical factors alone was 
0.91, whereas the full model incorporating genetic risk factors maintained an AUROC of 
0.96. 
 
 
 
 
 
Figure 4. Receiving operating characteristic (ROC) curve for the combined risk score 
for predicting hepatocellular carcinoma in NAFLD patients. A combined risk score 
considering acquired and common genetic risk factors was developed to predict HCC: 1 / (1 + 
e ^ - ((-12.588 + (0.162 * age) + (0.404 * Sex: 1 if male, -1 if female) + (0.259 * Obesity: 1 
present, -1 absent) + (0.587 * T2DM: 1 present, -1 absent) + (1.299 * Severe Fibrosis: 1 yes, -
1 no) + (0.442 * number of risk alleles))). The model had a 0.96 area under the ROC curve. 
The optimal cutoff had 96% sensitivity and 89% specificity for HCC in the present cohort. 
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4.1.5 Relationship between MBOAT7/TMC4 locus variants and gene expression 
In 98 severely obese patients, the rs641738 variant was in high linkage with the MBOAT7 3’-
UTR variant rs8736 C>T polymorphism (R
2
=0.98; only 1/98 discordant case).  Interestingly, 
in this subgroup rs8736 was more closely associated with NAFLD (p=0.048 vs. p=0.057) and 
MBOAT7 expression (p=0.042 vs. p=0.046) than rs641738. These data are in line with the 
hypothesis that rs641738 is not the causal variant, but may be in linkage with variants 
influencing MBOAT7 expression. 
In an experiment conducted by a colleague in our lab, gene expression of MBOAT7 was 
evaluated in 47 patients from the Hepatology service characterized by more severe liver 
damage (Table 6), results are shown in Figure 5. The rs641738 T allele was associated with 
reduced hepatic MBOAT7 expression in patients without moderate-severe fibrosis (stage F0-
F1; p=0.02), but not in those with significant fibrosis (stage F2-F4; p=0.1). 
 
Figure 5. Impact of the presence of rs643718 risk T allele on MBOAT7 expression. 
MBOAT7 expression was shown as log mRNA levels in 47 patients with NAFLD from the 
Milan Hepatology service stratified by the presence of clinically significant hepatic fibrosis 
(stage F2-F4). Data were compared by Student’s t-test. 
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4.1.6 Impact of rs641738 variant on HCC risk in non-cirrhotic patients with other liver 
diseases  
We finally evaluated the impact of the rs641738 T allele on HCC risk in non-cirrhotic patients 
with CHC and ALD. Results are presented in Table 14. We started evaluating a larger cohort 
of 1751 individuals with CHC and ALD, of whom 630 (36%) had cirrhosis and 363 (21%) 
had HCC (Table 2). In 25 of 363 cases (7%), HCC was detected in the absence of cirrhosis. 
The rs641738 T allele was associated with increased risk of HCC in patients without 
cirrhosis, independently of age, sex, and the etiology of liver disease (OR 1.93, 95% c.i. 1.07-
3.58; p=0.035), but not in those with cirrhosis (p=NS).  
We observed a similar trend for association of the T allele with non-cirrhotic HCC in patients 
with CHC and ALD analyzed separately (Table 15). The PNPLA3 I148M variant was also 
associated with HCC development outside cirrhosis (Table 14; p=0.021). 
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Table 14. Independent predictors of hepatocellular carcinoma (HCC) in 1751 patients 
with chronic liver disease (994 with chronic hepatitis C and 757 with alcoholic liver 
disease) stratified by the presence of cirrhosis (Validation cohort). 
 
Cirrhosis NO 
                                                     HCC 
 No 
(n=1,096) 
Yes  
(n=25) 
p value Allelic OR, 
95% c.i.* 
p value* 
PNPLA3 I148M  558/437/101 
(51/40/9) 
8/10/7 
(32/40/28) 
0.016 1.92, 1.07-
3.45  
0.021 
TM6SF2 E167K 973/122/1 
(89/11/0) 
20/5 
(80/20) 
0.16 1.96, 0.61-
5.27 
0.16 
MBOAT7/TMC4 
rs641738 C>T 
327/510/259 
(30/46/24) 
2/15/8 
(8/60/32) 
0.028 1.93, 1.07-
3.58 
0.035 
Cirrhosis YES 
                                                       HCC 
 No  
(n=291) 
Yes  
(n=338) 
p value Allelic OR, 
95% c.i.* 
p value* 
PNPLA3 I148M 111/126/54 
(38/43/19) 
137/143/58 
(41/42/17) 
0.91 1.04, 0.81-
1.34 
0.88 
TM6SF2 E167K 252/36/3 
(87/12/1) 
303/34/1 
(89/10/1) 
0.31 0.79, 0.47-
1.32 
0.32 
MBOAT7/TMC4 
rs641738 C>T 
78/155/58 
(28/51/21) 
117/150/71 
(35/44/21) 
0.96 1.01, 0.78-
1.30 
0.96 
 
( ): % values; OR: odds ratio; c.i.: confidence interval. Comparisons were performed by 
logistic regression setting HCC as dependent variable, and the association of genetic variants 
was analyzed assuming additive models. * Adjusted for age, sex, liver disease etiology, and 
PNPLA3, TM6SF2 and MBOAT7/TMC4 genetic variants. 
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Table 15. Independent predictors of hepatocellular carcinoma (HCC) in 994 with 
chronic hepatitis C (CHC) and 757 with alcoholic liver disease (ALD) stratified by the 
presence of cirrhosis. 
 
Chronic hepatitis C: Cirrhosis NO 
 HCC   
 No (n=584) Yes (n=13) p value p value* 
PNPLA3 I148M  313/219/52 
(54/37/9) 
5/5/3 
(38/39/24) 
0.18 0.22 
TM6SF2 E167K 538/46 
(92/8) 
9/4 
(69/31) 
0.032 0.008 
MBOAT7/TMC4 
rs641738 C>T 
177/259/148 
(30/45/25) 
1/7/5 
(8/54/38) 
0.087 0.071 
Chronic hepatitis C: Cirrhosis YES 
 HCC   
 No (n=160) Yes (n=237) p value p value* 
PNPLA3 I148M 74/65/21 
(46/41/13) 
113/97/27 
(48/41/11) 
0.74 0.76 
TM6SF2 E167K 142/18 
(89/11) 
221/16 
(93/7) 
0.18 0.18 
MBOAT7/TMC4 
rs641738 C>T 
45/84/31 
(28/53/19) 
84/102/51 
(35/43/22) 
0.96 0.94 
Alcoholic liver disease: Cirrhosis NO 
 HCC   
 No (n=512) Yes (n=12) p value p value* 
PNPLA3 I148M  245/218/49 
(48/43/9) 
3/5/4 
(25/42/33) 
0.054 0.041 
TM6SF2 E167K 435/76/1 
(85/15/0) 
11/1 
(92/8) 
0.58 0.41 
MBOAT7/TMC4 
rs641738 C>T 
150/251/111 
(29/49/22) 
1/8/3 
(8/67/25) 
0.12 0.090 
Alcoholic liver disease: Cirrhosis YES 
 HCC   
 No (n=131) Yes (n=101) p value p value* 
PNPLA3 I148M 37/61/33 
(28/47/25) 
24/46/31 
(24/45/31) 
0.35 0.33 
TM6SF2 E167K 110/18/3 
(84/14/2) 
82/18/1 
(81/18/1) 
0.97 0.98 
MBOAT7/TMC4 
rs641738 C>T 
33/71/27 
(25/54/21) 
33/48/20 
(33/47/20) 
0.68 0.59 
 
( ): % values; * Adjusted for age, sex, and PNPLA3, TM6SF2 and MBOAT7/TMC4 genetic 
variants. 
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4.2 Telomerase reverse transcriptase rare germline mutations and 
hepatocellular carcinoma in patients with nonalcoholic fatty liver disease 
4.2.1 Telomere length is reduced in peripheral blood leukocytes of NAFLD HCC patients 
Telomere length in peripheral blood leukocytes decreased with liver disease progression from 
healthy controls to NAFLD-cirrhosis to NAFLD-HCC (p=0.0003; ANOVA), even after 
adjustment for sex and age (p=0.0002; Figure 6A). In particular, telomere length was lower in 
HCC patients vs. cirrhosis (median: 0.93 IQR: 0.66-1.24 vs. 1.12 IQR: 0.82-1.69; p= 0.014) 
and vs. healthy subjects (median: 1.38 IQR: 0.99-1.75; p=0.0001). When we added an 
additional independent cohort of 50 Italian NAFLD-HCC, we observed the same shortening 
(p for trend=0.0008), with NAFLD-HCC patients having shorter telomeres as compared to 
those with uncomplicated cirrhosis and to healthy individuals (median: 0.98 IQR: 0.77-1.52; 
p= 0.048 and p= 0.0006, respectively; Figure 6B).  
In n=5 patients for whom intra-tumoral specimens were available, we investigated telomere 
length in the intra-tumoral tissue. As expected, we observed telomere elongation in HCC 
lesions compared to peripheral blood (p=0.05; Figure 6C). In these HCC specimens, 
telomeres elongation was not always due to somatic mutations in the hTERT promoter. 
Indeed, we analyzed the known hot spots of mutations at -124 and -146 from the hTERT 
origin and we found only one carrier of a variation in heterozygosity (-124 G>A).  
46 
 
 
Figure 6. Telomere length is reduced in peripheral blood leukocytes of NAFLD HCC 
patients. Relative telomere length of patients included in the Discovery cohort (panel A) and 
in the Overall cohort (panel B) have been reported in the figure. Overall cohort includes all 
the Italian NAFLD-HCC patients (see table 3). For the different comparison p values were 
calculated by linear generalized model corrected for sex and age considering log-transformed 
data (table 16). Comparison of telomere length between peripheral blood leukocytes and intra-
tumoral tissue has been shown in the figure (panel C). p value was calculated by Fisher 
paired T-test. For all the specimens, telomere length was evaluated by qPCR as ratio of the 
relative quantity of the telomere PCR product and the reference gene (36B4). 
Table 16. Values of significance relative to telomere length comparisons. 
 
 
 
 
 
 P value 
 Discovery Validation 
HCC vs Healthy 0.0001 0.0006 
HCC vs Cirrhosis 0.0144 0.048 
Cirrhosis vs Healthy 0.2364 - 
Liver disease vs Healthy 0.0067 0.0049 
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4.2.2 Rare hTERT coding mutations are enriched in NAFLD HCC patients 
We next evaluated the presence of rare hTERT coding variants in the discovery Italian cohort. 
We found three novel mutations and one mutation previously described in dbSNP with rare 
frequency. In particular, one patient had a heterozygous frameshift mutation, 
Glu113Arg_fs*79, in the second exon of the sequence. Three HCC patients carried missense 
mutations: Ala67Val, Pro193Leu and Glu668Asp. The homozygous Ala67Val and the 
heterozygous Pro193Leu are both located in the N-terminal (template binding domain). The 
Glu668Asp, found in heterozygosity, is located in the catalytic domain (Figure 7).  
Enrichment of these rare coding mutations was detected in NAFLD-HCC patients rather than 
in subjects with cirrhosis or healthy controls (prevalence 10%; p=0.022 vs. cirrhosis, p=0.008 
vs. healthy subjects; p=0.001 vs. controls overall). Burden test analysis confirmed the 
enrichment of rare hTERT coding mutations with HCC (p=0.020 vs healthy controls; p=0.045 
vs cirrhosis; Table 17). When we extended the control group to the 503 healthy European 
subjects from the 1000Genomes Project database ( 
http://www.internationalgenome.org/faq/can-i-get-phenotype-geneder-and-family-
relationship-information-samples ), in which only one individual of Italian origin was a 
heterozygous carrier of a rare coding mutation in hTERT, we confirmed a strong enrichment 
of missense variations in NAFLD-HCC (p=0.0001; Table 17). 
Interestingly, considering the distribution of known rare coding mutations in hTERT (see 
Telomere Database - http://telomerase.asu.edu), we observed an enrichment of variations in 
the N-terminal of the gene (p=0.037) as compared to catalytic and C-terminal domains. 
Besides rare variants, common missense mutations in hTERT were found in our cohort both in 
HCC patients, cirrhotic patients and healthy controls, at the expected frequencies (Ala279Thr, 
His412Tyr and Ala1062Thr; Table 18). 
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Figure 7. Rare coding mutations found in hTERT gene. Schematic representation of 
hTERT sequence showing the distribution of the rare coding mutations identified in the 
different domains (panel A). Electropherograms related to the identified rare coding 
mutations (panel B). The panel shows the mutated sequences in the upper part, while the 
corresponding normal sequences are represented below. 
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Table 17. Description of rare non-synonymous variations in hTERT gene found in subjects analyzed. The non-synonymous variations found in 
subjects sequenced are listed in the table, together with the only mutation found with frequency <0.001 in “European 1000G”. All the mutations have 
been described with a frequency lower than <0.001 in both the ExAC NFE and the ESP EA. The table indicates the number of mutated alleles for each 
variation in the different groups analyzed and in the public database of “European 1000G”. 
 
SNP (single nucleotide polymorphism); GRCh37 (human genome assembly release 37); Ref/Alt (Reference/Alternative allele); PLC (primary liver 
cancer); n.a. (number of alleles); *mutation in homozygosity; p values were calculated by Burden test considering HCCs vs Controls (healthy subjects 
and cirrhosis; °) and vs European 1000G (^); Overall p value was calculated by Burden test considering overall HCCs vs Controls (cirrhosis, healthy 
subjects and European 1000G). Variants were annotated according to hg19/GRCh37, using the hTERT RefSeq reference transcript NM_001193376. 
     Discovery  Validation  
Mutation 
SNP_ID 
(dbSNP147) 
Chr:Position 
(GRCh37) 
Ref/Alt 
European 
1000G 
(n.a.=1006) 
Healthy 
controls 
(n.a.=128) 
Cirrhosis 
(n.a.=90) 
HCC 
(n.a.=80) 
Discovery 
p value 
PLC 
(n.a.=156) 
Overall 
p value 
 
 
 
 
                     0.005° 
0.0001^ 
 0.0005 
Ala67Val* - 5:1294905 G/A - - - 2  -  
Glu113Argfs - 5:1294664 G/GG - - - 1  -  
Pro193Leu rs751762765 5:1294423 G/A - - - 1  -  
His296Pro rs778187343 5:1294114 T/G - - - -  1  
Glu668Asp - 5:1279532 C/G - - - 1  -  
Val897Met rs559028617 5:1264558 C/T 1 - - -  -  
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Table 18. Description of common non-synonymous variations in hTERT gene found in subjects analyzed. The non-synonymous variations 
found in subjects sequenced with a frequency higher than 0.1% in both the ExAC NFE and the ESP EA are listed in the table. The table indicates 
the number of mutated alleles for each variation in the different groups and in the public database of “European 1000G”. 
 
 
SNP (single nucleotide polymorphism);  GRCh37 (human genome assembly release 37); Ref/Alt (Reference/Alternative allele); PLC (primary liver 
cancer); n.a. (number of alleles); p values were calculated by Chi Square test considering HCCs vs Controls (healthy subjects and cirrhosis; 
§
) and 
vs European 1000G (*); Overall p value was calculated by Chi Square test considering overall HCCs vs Controls (cirrhosis, healthy subjects and 
European 1000G. Variants were annotated according to hg19/GRCh37, using the hTERT RefSeq reference transcript NM_001193376.
     Discovery  Validation  
Mutation 
SNP_ID 
(dbSNP147) 
Chr:Position 
(GRCh37) 
Ref/Alt 
European 
1000G 
(n.a.=1006) 
Healthy 
controls 
(n.a.=128) 
Cirrhosis 
(n.a.=90) 
HCC 
(n.a.=80) 
Discovery 
p value 
PLC 
(n.a.=156) 
Overall 
p value 
Ala279Thr rs61748181 5:1294166 C/T 36 4 3 2 
0.613* 
0.751
§
 
6 0.925 
His412Tyr rs34094720 5:1294166 C/T 3 1 - - 
0.625* 
0.544
§
 
- 0.842 
Ala1062Thr rs35719940 5:1254594 G/A 22 1 - - 
0.544* 
0.518
§
 
3 0.518 
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4.2.3 hTERT mutations in a European cohort of NAFLD-PLC patients 
We further sequenced hTERT in an independent cohort comprising 78 patients affected by 
PLC in NAFLD, 64% of Italian ancestry (Table 3). Here, we found one heterozygous carrier 
of a rare missense mutation (His296Pro; Figure 7) affected by intrahepatic 
cholangiocarcinoma. There was no significant enrichment in hTERT mutations between the 
validation cohort and controls of the Discovery cohort and healthy European subjects (p=0.42 
and p=0.25 respectively). However, when we considered the overall cohort of cancer patients 
(n=118), as compared to all available controls (from discovery cohort and the 1000Genomes 
database, n=612), we confirmed a significant enrichment of rare germline hTERT variants in 
subjects affected by tumor developed in NAFLD (p=0.0005; Table 17), which remained 
significant after the exclusion of cholangiocarcinoma patients (p=0.003). 
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4.2.4 Clinical features of patients carrying rare hTERT mutations 
The clinical features of patients positive and negative for the presence of the rare hTERT 
mutations are shown in Table 19. We found that the prevalence of female sex was higher in 
carriers of hTERT mutations (p=0.03). We did not observe any significant difference in the 
distribution of age, BMI, diabetes and the presence of cirrhosis between the two groups 
(p=NS). The genetic risk factor PNPLA3 I148M was equally distributed between the two 
groups (p=0.885). No significant differences were detected in peripheral blood telomere 
length between patients positive and those negative for hTERT mutations (not shown). 
 
Table 19. Clinical features of 118 patients who developed primary liver cancer (PLC) in 
NAFLD stratified by carriage of rare hTERT mutations. 
                 PLC cohort overall  
hTERT mutation yes  
(n=5) 
no 
(n=113) 
p 
Age, years 70.4±10.8 67.0±8.8 0.52 
Sex, F 3 (60) 21 (19) 0.03 
BMI, Kg/m
2
 28.8±5.0 29.9±5.3 0.65 
T2DM, y 3 (60) 66 (58)
 
0.94 
Fibrosis, F3-4 4 (80) 89 (79) 0.93 
PNPLA3, I148M   0.90 
I/I 1 (20) 30 (27)  
I/M 2 (40) 48 (42)  
M/M 2 (40) 35 (31)  
 
PLC: primary liver cancer; ( ): % values; y: yes; T2DM: type 2 diabetes mellitus; p: p value 
calculated as patients carriers of hTERT mutations versus not carriers. 
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4.2.5 Family study 
To investigate the causal effect of the mutations found, we examined whether these co-
segregated with liver disease or other pathological phenotypes. We were able to genotype and 
phenotype some relatives of the probands carrying the Glu668Asp (Family A, Figure 8) and 
the Glu113Argfs (Family B, Figure 8) mutations. In Family A, one son of the proband carried 
the mutation in heterozygosity and already showed traits of liver damage (NAFLD and 
increased liver enzymes) despite a relatively young age, while the nephew had a phenotype 
possibly related to mutations in hTERT, namely obstructive lung disease. The mother and the 
sister of the proband were affected by a phenotype likely related to telomere disease 
(cryptogenic cirrhosis and idiopathic pulmonary fibrosis, respectively). In Family B, the 
proband’s brother, who also carries the Glu113Argfs mutation, had altered liver function tests. 
One of her younger daughters and a nephew were carriers of the mutations in heterozygosity, 
but with no phenotypic signs, possibly due to the young age. 
 
 
 
 
Figure 8. Family study. Family trees of patients carriers of Glu668Asp and Glu113Argfs 
mutations (Family A and Family B respectively).  
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4.2.6 Functional evaluation of hTERT mutations 
In order to investigate whether the mutations found could affect the catalytic activity of 
hTERT, their effect was modelled in silico using predictive bioinformatics algorithms. In 
addition to the Glu113Argfs frameshift mutation, which causes a premature termination of 
protein synthesis and is frankly damaging, the Glu668Asp variant was also predicted to be 
deleterious by two out of three damage prediction tools (Table 20). Conversely, the amino 
acid substitutions Ala67Val, Pro193Leu and His296Pro were not predicted to influence the 
activity of the protein (Table 20), but we could not establish their impact on the DNA-binding 
of TERT. 
 
Table 20. In silico prediction of functional impact of hTERT mutations according to 
bioinformatics algorithms. 
 
 
 
 
 
 
 
 
 
 
To gain further insight into the consequences of hTERT mutations, the wild type and the 
missense mutants, which were generated by in situ mutagenesis or overlap extension PCR 
cloning, were transiently overexpressed in human HEK-293 cells by our collaborators from 
Professor Romeo’s Lab in Sweden. It was observed a substantial reduction in the intracellular 
 hTERT variants 
 Ala67Val Glu113Argfs Pro193Leu His296Pro Glu668Asp 
Polyphen2 Benign Damaging Benign Benign Probably 
damaging 
score 0.011  0.000 0.160 1.000 
SIFT Tolerated Damaging Tolerated Tolerated Damaging 
score 0.16  0.38 0.21 0.04 
Provean Neutral Deleterious Neutral Neutral Neutral 
score -1.210  -1.08 -1.025 -1.724 
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protein synthesis of the Ala67Val and Glu668Asp mutations as compared to the wild type 
protein (Figure 9). There was virtually no change in the protein synthesis of the Pro193Leu 
and His296Pro mutants when compared to the wild type protein (Figure 9).  
 
Figure 9. The hTERT Ala67Val and Glu668Asp variants result in a reduction of the 
intracellular protein levels. Effect of missense mutations on hTERT protein levels in HEK-
293 cells (panel A). Human TERT was transiently overexpressed in HEK-293 cells. HEK-
293 cells were transfected with hTERT wild type and mutant forms cloned in pcDNA 3.1 
vector for 48h; recombinant hTERT protein levels were examined on cell lysate by Western 
blotting analysis by using a V5 antibody. Empty vector was used as negative and calnexin 
was used as loading control. Quantification of Western blotting bands (panel B). The graph 
bar represents intracellular protein levels expressed as mean and standard deviation (whisker) 
of three independent experiments. Protein levels was quantified by Image Lab Software (Bio-
Rad). 
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5. Discussion 
5.1 The MBOAT7 rs641738 variant associates with NAFLD-HCC  
5.1.1 Speculated mechanisms and clinical implications 
In the first part of this study, we evaluated whether the rs641738 C>T MBOAT7 locus 
sequence variant, associated with the development and progression of NAFLD [51], 
influences susceptibility to NAFLD-HCC in patients stratified by the severity of liver fibrosis. 
We found that each MBOAT7 rs641738 T allele conferred an approximately 80% increased 
risk of HCC (65% when taking into consideration also the impact of liver fibrosis). 
The MBOAT7 protein catalyzes the transfer of polyunsaturated fatty acids such as 
arachidonoyl-CoA to lyso-phosphatidylinositol, thereby allowing to achieve an adequate level 
of desaturation [51]. The rs641738 T allele is associated with reduced MBOAT7 expression 
and altered phosphatidyl-inositol plasma and hepatic composition [51, 62]. Of note, we 
detected a significant interaction between MBOAT7 genotype and the presence of obesity in 
determining HCC risk, in line with the hypothesis that the phenotypic expression of the 
mutation is triggered by the increased flux of fatty acids to the liver. Therefore, the 
mechanism underpinning the association of the MBOAT7 rs641738 sequence variant with 
NAFLD-HCC may be mediated by changes in phosphatidyl-inositol and arachidonic acid 
metabolism, favoring hepatocellular fat accumulation and the production of inflammatory 
mediators [51]. However, rs641738 is not likely the causal variant underpinning susceptibility 
to NAFLD and HCC, as we observed that it is in strong linkage with other polymorphisms in 
the 3’-UTR of MBOAT7, which may be more closely related to the phenotype and are 
potentially involved in the regulation of MBOAT7 mRNA stability. 
An important finding is that the effect size of rs641738 on HCC risk may have been larger in 
patients without severe fibrosis because the presence of the risk variant may somewhat 
compensate for the lack of the cirrhotic pro-carcinogenic environment. We also observed that 
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the rs641738 T allele is associated with reduced hepatic expression of MBOAT7 only in 
NAFLD patients without severe fibrosis. It could therefore be speculated that the MBOAT7 
variant exerts its deleterious effect specifically at early stages of liver disease. Alteration of 
hepatic parenchymal structure and relative cell-types representation may then hamper the 
impact of the MBOAT7 variant during severe fibrosis, because MBOAT7 is highly expressed 
in hepatic stellate cells and inflammatory cells [51, 101]. In keeping with this hypothesis, we 
also showed that the rs641738 T allele was associated with HCC development in non-
cirrhotic patients with ALD or CHC, although further studies are necessary to clarify whether 
genotyping of the MBOAT7 variant may be useful to stratify disease risk in patients cured 
from chronic hepatitis C. Consistently, the rs641738 T allele was also associated with 
development of early stages, but not severe fibrosis in patients at risk of NASH [51], and in a 
large cohort of CHC patient [102]. Therefore, it could be speculated that MBOAT7 variation 
have a dual impact on liver disease during initial stages: either predisposes to HCC 
development before severe fibrosis ensues, or it facilitates the evolution to early-intermediate 
fibrosis, which however subsequently hampers the impact of this genetic variant. 
 
5.1.2 Common genetic variants in PNPLA3, TM6SF2 and MBOAT7 are risk factors for 
HCC 
In the NAFLD cohort, the overall impact of the MBOAT7 rs641738 on HCC risk was similar 
to that of the I148M PNPLA3 variant. Indeed, MBOAT7 and PNPLA3 variants explained 
about 27% and 22%, respectively, of HCC phenotype variability. However, the effect of the 
I148M variant on HCC risk was not independent of severe fibrosis, suggesting that the 
mechanism is partly mediated by promotion of hepatic fibrogenesis and alteration of hepatic 
stellate cells biology [34, 39, 103]. Notably, the size effect of the PNPLA3 I148M variant was 
larger and only partially attenuated by the impact on liver fibrosis in a previous study 
conducted in a UK cohort [41]. This difference may be due to lifestyle factors, and to the 
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higher prevalence of clinical cofactors (obesity, T2DM, and cirrhosis) as opposed to genetic 
risk variants (lower frequency of the I148M variant) in the UK cohort. Notwithstanding, a 
pooled estimate of the effect of the I148M variant in the UK and Italian cohort confirmed an 
increased HCC susceptibility independently of fibrosis. In addition, we also report for the first 
time an association between the TM6SF2 E167K variant and NAFLD-HCC, which was 
independent of severe fibrosis. This was not observed at univariate analysis due to an 
interaction of the TM6SF2 variant with clinical factors, and in the UK NAFLD cohort [47], 
whereas a predisposing effect on HCC was reported in a Italian cohort of patients with 
alcoholic cirrhosis [49]. Further studies are therefore required to confirm whether the E167K 
variant is an independent risk factor for HCC.  
However, we found that, independently of any acquired factor, the number of genetic risk 
variants in PNPLA3, TM6SF2 and MBOAT7 was able to classify NAFLD patients in three 
groups with very different HCC risk: 9% in the 36% with 0-1 risk alleles, l9% in the 55% 
with 2-3 risk alleles, and 31% in those with more than 3 risk alleles. 
 
5.1.3 Study’ s limitations 
Limitations include the cross-sectional retrospective nature of the study resulting, very 
similarly to what was observed in independent studies [41], in an uneven representation of 
clinical risk factors (age, sex, T2DM, severe fibrosis) between HCC cases and controls with 
histological NAFLD. However, the majority of NAFLD-HCC patients are still diagnosed 
incidentally outside regular follow-up [104], so that prospective studies in patients with 
advanced disease would not be more informative, especially for the risk of non-cirrhotic 
NAFLD-HCC. This could have led to an underestimation of the impact of inherited genetic 
risk variants on NAFLD-HCC, whereas the impact of clinical risk factors may have been 
overestimated. Therefore, the weight of specific factors in determining the HCC risk score 
should be reassessed in larger prospective cohorts with long follow-up and availability of the 
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genetic risk profile before the evaluation of genetic risk variants can be considered for 
implementation in clinical practice. Finally, these results may not be applicable to other ethnic 
groups. 
 
5.2 hTERT rare germline mutations and telomere attrition are risk factor 
for NAFLD-HCC 
5.2.1 Role of telomere in HCC pathogenesis 
In the second part of the study we firstly assessed whether telomere attrition, a known feature 
of liver fibrosis, predisposes to NAFLD-HCC development. 
We observed a progressive shortening of peripheral telomere length, from healthy controls to 
patients with cirrhosis related to NAFLD and in particular to those who developed HCC. In 
keeping with these observations, previous studies demonstrated that telomere attrition is 
involved in the progression of liver disease, as well as in other chronic degenerative 
conditions [65, 66, 70, 74, 105]. Indeed, shorter telomeres lead to the exhaustion of tissue 
staminal compartments,  senescence, and fibrosis, which may involve the lung, liver and 
blood, and predispose to a wide spectrum of cancers by favoring genomic instability [106]. 
Not only genetic alterations in Telomerase complex genes, but also environmental risk factors 
for degenerative diseases, such as smoke and pollution, have been associated with peripheral 
blood telomere shortening, reflecting whole body exposure [105, 107]. It is therefore possible 
that shorter telomeres may reflect both genetic predisposition and environmental factors 
exposure in NAFLD-HCC patients. 
Since reactivation of hTERT plays a key role in the immortalization of hepatocytes during 
malignant transformation [55, 73, 74], as expected we observed a re-elongation of telomeres 
within neoplastic lesions in a subgroup of patients. This was not frequently accounted for by 
hTERT promoter mutations, found in only one patient. It could be speculated that alternative 
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mechanisms of telomere elongation, such as insertional mutagenesis or duplication, or 
activation of the alternative lengthening of telomeres or the increase expression of other 
proteins of the telomerase complex may be involved [108-110]. 
 
5.2.2 hTERT rare germline mutations predispose to HCC 
NAFLD and HCC have a strong heritable component and rare genetic mutations may play a 
role in triggering disease development [10, 30, 61]. Therefore, in this part of the study we 
evaluated whether mutations in hTERT, a key player in hepatic fibrosis progression and 
carcinogenesis [57, 59, 65, 111], are associated with NAFLD-HCC development.  
We focused on rare germline mutations determining an alteration of protein sequence because 
these are more likely to alter protein function [112, 113]. Consistently, in the NAFLD-HCC 
discovery cohort, we observed a strong enrichment in rare and novel hTERT mutations, 
almost 76-fold as compared to the frequency of analogous mutations in local controls and 
healthy individuals of matched ethnicity in public databases. In further analysis, we 
considered as population controls only apparently healthy Europeans individuals included in 
the 1000Genomes database. These data are consistent with the hypothesis that rare hTERT 
mutations predispose to NAFLD-HCC. 
The frequency of hTERT mutations was lower in a larger European validation cohort, but 
amongst NAFLD-PLC patients overall there still was a significant 31-fold enrichment in 
hTERT mutations. The higher prevalence of mutations in the discovery cohort may possibly 
be ascribed to the higher proportion of individuals without strong cofactors for progressive 
NAFLD such as obesity and male sex, so that genetic factors may have played a larger role. 
Interestingly, despite HCC more frequently developing in males, we observed a strikingly 
higher prevalence of hTERT mutations in female patients with NAFLD-PLC, so that the lower 
proportion of females in the validation cohort may have reduced the probability of finding 
mutations carriers. As one mutation carrier was actually diagnosed with intrahepatic 
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cholangiocarcinoma, we cannot exclude the possibility that hTERT genetic variations 
represent a common pathogenic risk factor for PLC. 
On the other hand, common missense variants in hTERT, including Ala279Thr, His412Tyr 
and Ala1062Thr, previously reported to confer increased risk of telomere disease [114-118], 
were not differently represented between HCC cases and healthy controls. Even if these 
genetic variants may possibly confer subtle alterations in hTERT activity, we can reasonably 
exclude that they have a strong impact on telomere dysfunction; otherwise they would have 
undergone a strong negative selection (purification) during evolution. Our study was not 
sufficiently powered to detect a moderate effect on the risk of progressive NAFLD. 
 
5.2.3 Effects of the rare germline mutations identified in hTERT 
Several clues, besides the fact itself that are rare or novel mutations, suggest that the genetic 
variants identified may have played a role in the pathogenesis of NAFLD-HCC. The first one 
is that mutations tended to co-segregate within the N-terminal domain of hTERT, which is 
involved in telomere binding. Indeed, it is know that mutations in specific hTERT domains 
tend to determine specific pathological phenotypes [106]. Secondly, mutations co-segregated 
with liver disease and other phenotypes shared by telomere diseases in older individuals. As 
telomeropathies are age-dependent degenerative conditions, a longer follow-up will be 
necessary to better characterize the penetrance of these genetic variants in younger carriers. 
Furthermore, in silico analysis predicted functional consequences for Glu113Arg_fs, 
determining an early termination of the protein, and the Glu668Asp mutation in the catalytic 
domain. However, the ability of bioinformatics tools to predict the interaction of the other N-
terminal domain mutations with telomeres and interacting proteins is quite limited. 
To gain further insight into the functional consequences of hTERT mutations, we transiently 
overexpressed the wild type and the missense variants. We did not test in vitro the 
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Glu113Argfs*79 mutation because of the high likelihood to undergo mRNA decay due to the 
severe damage caused by the frameshift [119]. We observed that the Ala67Val and the 
Glu668Asp mutations resulted in a severe reduction in the intracellular protein levels as 
compared to the wild type, suggesting that the Ala67Val, carried in homozygosity by one 
NAFLD-HCC patient, may induce a reduction in telomerase activity due to altered protein 
translation or stability.  On the other hand, the Pro193Leu and the His296Pro mutations in the 
N-terminal template binding domain, do not likely influence the catalytic activity of hTERT, 
but may result in a reduction of the binding ability of hTERT, inducing novel telomerase 
functions in tumorigenesis independently of hTERC [120]. For example, hTERT can act as a 
transcription factor in the Wnt-β-catenin signaling pathway, regulating the expression of pro-
carcinogenic Wnt target genes [121, 122]. Our bioinformatics and in vitro approach was not 
suitable to test these hypotheses, therefore further studies are required to better investigate 
their possible causal role and mechanism in determining HCC predisposition. 
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6. Conclusion 
Family history and genetic factors play an important roles in the pathogenesis of progressive 
NAFLD and of HCC [10, 30], however there is a lack of a common prognostic marker able to 
identify NAFLD patients at risk to progress towards cancer.  
In this study, we demonstrated that common and rare genetic variants may have a role in 
influencing the pathogenesis of this rare disease characterized by increasing incidence in 
Western countries.  
An important finding is that the MBOAT7 rs641738 C>T polymorphism increased HCC risk 
in European NAFLD specifically in patients without severe fibrosis and it was associated with 
reduced MBOAT7 expression. This data was confirmed also in non-cirrhotic patients affected 
by other liver diseases (ALD and CHC). This genetic polymorphism may thus represent a 
useful biomarker to identify individuals at HCC risk in patients presenting without advanced 
liver damage, which is an important clinical problem in the management of patients with 
NAFLD. 
Furthermore, the number of genetic risk variants in PNPLA3, TM6SF2, and MBOAT7 carried 
by patients with NAFLD was associated with HCC risk independently of cofactors, with 13.4-
fold higher risk in those carrying the maximum number of variants as compared to none. 
These data suggest that genetic variants predisposing to hepatic fat accumulation promote 
hepatic carcinogenesis. Indeed, hepatocellular fat accumulation seems to represent a key 
feature of hepatic carcinogenesis [123, 124]. Therefore, all in all they might represent useful 
biomarkers for risk stratification, performing better than the PNPLA3 I148M variant alone, 
which was proposed by the EASL-EASD-EASO NAFLD guidelines [41, 83]. However, in 
the present retrospective cohort genetic risk variants did not significantly improve the 
predictive accuracy of clinical factors. Large prospective studies are necessary to evaluate 
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whether combined evaluation of genetic and acquired risk factors may improve HCC risk 
stratification for patients with NAFLD and non-cirrhotic liver disease.  
For what concern the second part of the study, our results suggest that telomere attrition is 
associated with NAFLD-HCC development, and that rare germline mutations in hTERT 
predispose to cirrhosis progression towards HCC in some familial cases, potentially assisting 
the identification of high-risk individuals that may warrant closer surveillance. Our hypothesis 
for the role of telomere and telomerase in HCC pathogenesis is the following one. Triggering 
factors, such as obesity and insulin resistance in the case of NAFLD, induce a condition of 
chronic hepatic damage and regeneration characterized by progressive hepatocytes telomere 
shortening and senescence. When hepatocytes reach senescence, liver regeneration decreases, 
but chronic damage remains. Concomitantly, other cell types, such as HSCs, become 
activated and form fibrotic tissue in area of hepatocytes loss. In this context, germline hTERT 
loss-of-function mutations accelerate telomere shortening favoring fibrosis development and 
thus creating a favorable microenvironment for cancer onset. Moreover telomeres attrition 
and germline hTERT loss-of-function mutations may exert a direct pro-carcinogenic effect by 
promoting genomic instability both inducing telomere shortening and impairing Telomerase 
activity in DNA repair and chromatin organization [72]. Within this context, the presence of 
heterozygous mutations does not prevent the reactivation of Telomerase wild type allele at 
later stages of carcinogenesis, which is necessary for the indefinite replication of the 
neoplastic clone (Figure 10)[55]. As many other proteins are included in Telomerase complex 
and participate to telomere elongation, we cannot exclude that mutations in other genes 
involved in telomere regulation play a role in telomere attrition in NAFLD-HCC. Indeed, 
telomere length in peripheral blood was shortened irrespective of the presence of hTERT 
mutations in NAFLD-HCC patients. Additional genetic factors should be investigated by next 
generation sequencing. Indeed, our approach suggests that rare germline mutations altering 
65 
 
the sequence of protein known to be involved in the pathogenesis of NAFLD and chronic 
liver disease may play an important role in NAFLD-HCC predisposition. 
 
 
Figure 10. Hypothesis for telomeres role in pathogenesis of NAFLD progression toward 
cirrhosis and HCC. 
 
In conclusion, these findings suggest that common genetic variants, such as MBOAT7 
rs641738 and the other ones associated with hepatic fat accumulation, are biomarkers able to 
improve HCC screening by assisting in the identification of subjects at risk even in the 
absence of severe fibrosis, most likely in different etiologies of liver disease. Moreover, these 
data suggest that rare mutations, such as those in hTERT gene, and strong heritable tracts, 
such as telomere length, influence HCC development and may play an important role for risk 
stratification particularly in family members of affected individuals. All in all, these results 
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pave the way for new potential therapeutic targets. At this purpose in future, functional 
studies are needed in order to identify the precise molecular mechanisms that underlie the 
pathogenesis of NAFLD-HCC and to understand the exact role and the interplay of the 
several common and rare genetic variants that contribute to the onset and the progression of 
this rare and complex disease. 
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